Radiant Sage Adds Event Adjudication Committee Solution
Radiant Sage, a provider of on-demand clinical trial imaging infrastructure solutions, announced its Event Adjudication Committee (EAC) solution for its RadClinica Clinical Trial Management System (CTMS).
Radiant Sage, a provider of on-demand clinical trial imaging infrastructure solutions, announced its Event Adjudication Committee (EAC) solution for its RadClinica Clinical Trial Management System (CTMS). The new module provides an electronic solution to automate the event adjudication process.
The EAC solution will be offered as an add-on module to customize workflows and quality assurance based on specific types of events. It acquires the required documentation (including images) associated to each event, verifies that the necessary data has been uploaded, initiates the QA review tasks (i.e. redactions, translation), and then enables project managers to create the review package. The system offers management and reporting tools to provide the entire clinical team oversight of the process.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
